A randomised double blind placebo controlled phase III study assessing the efficacy and safety of the investigational drug ZD4054, a specific endothelin A receptor antagonist, in patients with non-metastatic hormone resistant prostate cancer.

Inclusion/Exclusion Criteria

Confirmed Prostate Cancer

Progressing despite castrate status (medical or surgical)

No evidence of metastatic disease

clinicaltrials.gov: NCT00626548: http://clinicaltrials.gov/

Cancer Research UK: www.cancerhelp.org.uk/trials/trials/default.asp

emergingmed.com: www.emergingmed.com/ or call 1.877.601.8601

Please log-in or register in order to submit comments.

Powered by AkoComment!